Text Size

A Study To Evaluate The Mechanism Of Action Of CP-690,550 In Patients With Rheumatoid Arthritis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00976599
First received: September 11, 2009
Last updated: December 4, 2012
Last verified: December 2012
History of Changes
Results First Received: December 4, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Pharmacodynamics Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Basic Science
Condition: Rheumatoid Arthritis
Interventions: Drug: CP-690,550 + methotrexate
Drug: Placebo + Methotrexate

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
CP-690,550 CP-690,550 10 milligram (mg) tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.
Placebo Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.

Participant Flow:   Overall Study
    CP-690,550     Placebo  
STARTED     15     14  
COMPLETED     15     14  
NOT COMPLETED     0     0  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
CP-690,550 CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.
Placebo Placebo matched to CP-690,550 10 mg tablet orally twice daily up to Day 27 followed by single oral dose on Day 28.
Total Total of all reporting groups

Baseline Measures
    CP-690,550     Placebo     Total  
Number of Participants  
[units: participants]
 		  15     14     29  
Age  
[units: years]
Mean ± Standard Deviation 		  53.5  ± 9.2     53.1  ± 14.3     53.3  ± 11.7  
Gender  
[units: participants]
 		     
Female     14     12     26  
Male     1     2     3  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change From Baseline in Synovial Tissue Messenger Ribonucleic Acid (mRNA) Expression at Day 28   [ Time Frame: Day -7 (Baseline), Day 28 ]
  Show Outcome Measure 1

2.  Primary:   Change From Baseline in Protein Expression of Tumor Necrosis Factor Alpha (TNFalpha), Interleukin-6 (IL-6), Interleukin-17a (IL-17a) and Interleukin-10 (IL-10) at Day 28   [ Time Frame: Baseline (Day -7), Day 28 ]
  Show Outcome Measure 2

3.  Primary:   Change From Baseline in Percentage of Area Stained For CD3+ and CD68+ Surface Markers of Inflammatory Cells of the Synovial Tissue at Day 28   [ Time Frame: Baseline (Day -7), Day 28 ]
  Show Outcome Measure 3

4.  Primary:   Blood Levels for Gene Expression (Messenger Ribonucleic Acid [mRNA]) at Baseline (Day-7)   [ Time Frame: Baseline (Day -7) ]
  Show Outcome Measure 4

5.  Primary:   Blood Levels for Gene Expression (Messenger Ribonucleic Acid [mRNA]) at Day 28   [ Time Frame: Day 28 ]
  Show Outcome Measure 5

6.  Primary:   Blood Cytokine Level at Pre-dose on Day 1   [ Time Frame: Pre-dose on Day 1 ]
  Show Outcome Measure 6

7.  Primary:   Blood Cytokine Level at 1 Hour Post-dose on Day 1   [ Time Frame: 1 hour post-dose on Day 1 ]
  Show Outcome Measure 7

8.  Primary:   Blood Cytokine Level at 4 Hours Post-dose on Day 1   [ Time Frame: 4 hours post-dose on Day 1 ]
  Show Outcome Measure 8

9.  Primary:   Blood Cytokine Level at Pre-dose on Day 10   [ Time Frame: Pre-dose on Day 10 ]
  Show Outcome Measure 9

10.  Primary:   Blood Cytokine Level at Pre-dose on Day 28   [ Time Frame: Pre-dose on Day 28 ]
  Show Outcome Measure 10

11.  Primary:   Blood Cytokine Level at 1 Hour Post-dose on Day 28   [ Time Frame: 1 Hour Post-dose on Day 28 ]
  Show Outcome Measure 11

12.  Primary:   Blood Cytokine Level at 4 Hours Post-dose on Day 28   [ Time Frame: 4 Hours Post-dose on Day 28 ]
  Show Outcome Measure 12

13.  Primary:   Blood Cytokine Level at 8 Hours Post-dose on Day 28   [ Time Frame: 8 Hours Post-dose on Day 28 ]
  Show Outcome Measure 13

14.  Primary:   Blood Cytokine Level at 24 Hours Post-dose on Day 28   [ Time Frame: 24 Hours Post-dose on Day 28 ]
  Show Outcome Measure 14

15.  Primary:   Blood Cytokine Level at Pre-dose on Day 35 or Early Termination   [ Time Frame: Pre-dose on Day 35 or Early Termination ]
  Show Outcome Measure 15

16.  Primary:   Blood T, B and NK Lymphocyte Counts at Pre-dose on Day 1   [ Time Frame: Pre-dose on Day 1 ]
  Show Outcome Measure 16

17.  Primary:   Blood T, B and NK Lymphocyte Counts at 1 Hour Post-dose on Day 1   [ Time Frame: 1 Hour Post-dose on Day 1 ]
  Show Outcome Measure 17

18.  Primary:   Blood T, B and NK Lymphocyte Counts at 4 Hours Post-dose on Day 1   [ Time Frame: 4 Hours Post-dose on Day 1 ]
  Show Outcome Measure 18

19.  Primary:   Blood T, B and NK Lymphocyte Counts at Pre-dose on Day 10   [ Time Frame: Pre-dose on Day 10 ]
  Show Outcome Measure 19

20.  Primary:   Blood T, B and NK Lymphocyte Counts at Pre-dose on Day 28   [ Time Frame: Pre-dose on Day 28 ]
  Show Outcome Measure 20

21.  Primary:   Blood T, B and NK Lymphocyte Counts at 1 Hour Post-dose on Day 28   [ Time Frame: 1 Hour Post-dose on Day 28 ]
  Show Outcome Measure 21

22.  Primary:   Blood T, B and NK Lymphocyte Counts at 4 Hours Post-dose on Day 28   [ Time Frame: 4 Hours Post-dose on Day 28 ]
  Show Outcome Measure 22

23.  Primary:   Blood T, B and NK Lymphocyte Counts at 8 Hours Post-dose on Day 28   [ Time Frame: 8 Hours Post-dose on Day 28 ]
  Show Outcome Measure 23

24.  Primary:   Blood T, B and NK Lymphocyte Counts at 24 Hours Post-dose on Day 28   [ Time Frame: 24 Hours Post-dose on Day 28 ]
  Show Outcome Measure 24

25.  Primary:   Blood T, B and NK Lymphocyte Counts and Possible Subsets at Pre-dose on Day 35 or Early Termination   [ Time Frame: Pre-dose on Day 35 or Early Termination ]
  Show Outcome Measure 25

26.  Primary:   Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at Pre-dose on Day 1   [ Time Frame: Pre-dose on Day 1 ]
  Show Outcome Measure 26

27.  Primary:   Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at 1 Hour Post-dose on Day 1   [ Time Frame: 1 Hour Post-dose on Day 1 ]
  Show Outcome Measure 27

28.  Primary:   Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at 4 Hours Post-dose on Day 1   [ Time Frame: 4 Hours Post-dose on Day 1 ]
  Show Outcome Measure 28

29.  Primary:   Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at Pre-dose on Day 10   [ Time Frame: Pre-dose on Day 10 ]
  Show Outcome Measure 29

30.  Primary:   Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at Pre-dose on Day 28   [ Time Frame: Pre-dose on Day 28 ]
  Show Outcome Measure 30

31.  Primary:   Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at 1 Hour Post-dose on Day 28   [ Time Frame: 1 Hour Post-dose on Day 28 ]
  Show Outcome Measure 31

32.  Primary:   Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at 4 Hours Post-dose on Day 28   [ Time Frame: 4 Hours Post-dose on Day 28 ]
  Show Outcome Measure 32

33.  Primary:   Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at 8 Hours Post-dose on Day 28   [ Time Frame: 8 Hours Post-dose on Day 28 ]
  Show Outcome Measure 33

34.  Primary:   Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at 24 Hours Post-dose on Day 28   [ Time Frame: 24 Hours Post-dose on Day 28 ]
  Show Outcome Measure 34

35.  Primary:   Matrix Metallopeptidase 3 (MMP3), Osteocalcin and Osteopontin Levels at Pre-dose on Day 35 or Early Termination   [ Time Frame: Pre-dose on Day 35 or Early Termination ]
  Show Outcome Measure 35

36.  Primary:   Parathyroid Hormone (PTH) Level at Pre-dose on Day 1   [ Time Frame: Pre-dose on Day 1 ]
  Show Outcome Measure 36

37.  Primary:   Parathyroid Hormone (PTH) Level at 1 Hour Post-dose on Day 1   [ Time Frame: 1 Hour Post-dose on Day 1 ]
  Show Outcome Measure 37

38.  Primary:   Parathyroid Hormone (PTH) Level at 4 Hours Post-dose on Day 1   [ Time Frame: 4 Hours Post-dose on Day 1 ]
  Show Outcome Measure 38

39.  Primary:   Parathyroid Hormone (PTH) Level at Pre-dose on Day 10   [ Time Frame: Pre-dose on Day 10 ]
  Show Outcome Measure 39

40.  Primary:   Parathyroid Hormone (PTH) Level at Pre-dose on Day 28   [ Time Frame: Pre-dose on Day 28 ]
  Show Outcome Measure 40

41.  Primary:   Parathyroid Hormone (PTH) Level at 1 Hour Post-dose on Day 28   [ Time Frame: 1 Hour Post-dose on Day 28 ]
  Show Outcome Measure 41

42.  Primary:   Parathyroid Hormone (PTH) Level at 4 Hours Post-dose on Day 28   [ Time Frame: 4 Hours Post-dose on Day 28 ]
  Show Outcome Measure 42

43.  Primary:   Parathyroid Hormone (PTH) Level at 8 Hours Post-dose on Day 28   [ Time Frame: 8 Hours Post-dose on Day 28 ]
  Show Outcome Measure 43

44.  Primary:   Parathyroid Hormone (PTH) Level at 24 Hours Post-dose on Day 28   [ Time Frame: 24 Hours Post-dose on Day 28 ]
  Show Outcome Measure 44

45.  Primary:   Parathyroid Hormone (PTH) Level at Pre-dose on Day 35 or Early Termination   [ Time Frame: Pre-dose on Day 35 or Early Termination ]
  Show Outcome Measure 45

46.  Primary:   Osteoprotegerin (OPG) Level at Pre-dose on Day 1   [ Time Frame: Pre-dose on Day 1 ]
  Show Outcome Measure 46

47.  Primary:   Osteoprotegerin (OPG) Level at 1 Hour Post-dose on Day 1   [ Time Frame: 1 Hour Post-dose on Day 1 ]
  Show Outcome Measure 47

48.  Primary:   Osteoprotegerin (OPG) Level at 4 Hours Post-dose on Day 1   [ Time Frame: 4 Hours Post-dose on Day 1 ]
  Show Outcome Measure 48

49.  Primary:   Osteoprotegerin (OPG) Level at Pre-dose on Day 10   [ Time Frame: Pre-dose on Day 10 ]
  Show Outcome Measure 49

50.  Primary:   Osteoprotegerin (OPG) Level at Pre-dose on Day 28   [ Time Frame: Pre-dose on Day 28 ]
  Show Outcome Measure 50

51.  Primary:   Osteoprotegerin (OPG) Level at 1 Hour Post-dose on Day 28   [ Time Frame: 1 Hour Post-dose on Day 28 ]
  Show Outcome Measure 51

52.  Primary:   Osteoprotegerin (OPG) Level at 4 Hours Post-dose on Day 28   [ Time Frame: 4 Hours Post-dose on Day 28 ]
  Show Outcome Measure 52

53.  Primary:   Osteoprotegerin (OPG) Level at 8 Hours Post-dose on Day 28   [ Time Frame: 8 Hours Post-dose on Day 28 ]
  Show Outcome Measure 53

54.  Primary:   Osteoprotegerin (OPG) Level at 24 Hours Post-dose on Day 28   [ Time Frame: 24 Hours Post-dose on Day 28 ]
  Show Outcome Measure 54

55.  Primary:   Osteoprotegerin(OPG) Level at Pre-dose on Day 35 or Early Termination   [ Time Frame: Pre-dose on Day 35 or Early Termination ]
  Show Outcome Measure 55

56.  Primary:   Plasma Level of Matrix Metallopeptidase (MMP13)   [ Time Frame: Pre-dose on Day 1, 10, 28 and 35 or Early Termination; 1, 4 hours Post-dose on Day 1, 28; 8, 24 hours Post-dose on Day 28 ]
  Show Outcome Measure 56

57.  Primary:   Plasma Level of Interleukin-34 (IL-34) and Interleukin-18 (IL-18)   [ Time Frame: Pre-dose on Day 1, 10, 28 and 35 or Early Termination; 1, 4 hours Post-dose on Day 1, 28; 8, 24 hours Post-dose on Day 28 ]
  Show Outcome Measure 57

58.  Primary:   Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at Pre-dose on Day 1   [ Time Frame: Pre-dose on Day 1 ]
  Show Outcome Measure 58

59.  Primary:   Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at 1 Hour Post-dose on Day 1   [ Time Frame: 1 Hour Post-dose on Day 1 ]
  Show Outcome Measure 59

60.  Primary:   Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at 4 Hours Post-dose on Day 1   [ Time Frame: 4 Hours Post-dose on Day 1 ]
  Show Outcome Measure 60

61.  Primary:   Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at Pre-dose on Day 10   [ Time Frame: Pre-dose on Day 10 ]
  Show Outcome Measure 61

62.  Primary:   Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at Pre-dose on Day 28   [ Time Frame: Pre-dose on Day 28 ]
  Show Outcome Measure 62

63.  Primary:   Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at 1 Hour Post-dose on Day 28   [ Time Frame: 1 Hour Post-dose on Day 28 ]
  Show Outcome Measure 63

64.  Primary:   Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at 4 Hours Post-dose on Day 28   [ Time Frame: 4 Hours Post-dose on Day 28 ]
  Show Outcome Measure 64

65.  Primary:   Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at 8 Hours Post-dose on Day 28   [ Time Frame: 8 Hours Post-dose on Day 28 ]
  Show Outcome Measure 65

66.  Primary:   Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at 24 Hours Post-dose on Day 28   [ Time Frame: 24 Hours Post-dose on Day 28 ]
  Show Outcome Measure 66

67.  Primary:   Serum Amyloid A (SAA) and Carboxy-Terminal Collagen Crosslinks-1 (CTX-1) Levels at Pre-dose on Day 35 or Early Termination   [ Time Frame: Pre-dose on Day 35 or Early Termination ]
  Show Outcome Measure 67

68.  Primary:   Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at Pre-dose on Day 1   [ Time Frame: Pre-dose on Day 1 ]
  Show Outcome Measure 68

69.  Primary:   Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at 1 Hour Post-dose on Day 1   [ Time Frame: 1 Hour Post-dose on Day 1 ]
  Show Outcome Measure 69

70.  Primary:   Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at 4 Hours Post-dose on Day 1   [ Time Frame: 4 Hours Post-dose on Day 1 ]
  Show Outcome Measure 70

71.  Primary:   Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at Pre-dose on Day 10   [ Time Frame: Pre-dose on Day 10 ]
  Show Outcome Measure 71

72.  Primary:   Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at Pre-dose on Day 28   [ Time Frame: Pre-dose on Day 28 ]
  Show Outcome Measure 72

73.  Primary:   Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at 1 Hour Post-dose on Day 28   [ Time Frame: 1 Hour Post-dose on Day 28 ]
  Show Outcome Measure 73

74.  Primary:   Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at 4 Hours Post-dose on Day 28   [ Time Frame: 4 Hours Post-dose on Day 28 ]
  Show Outcome Measure 74

75.  Primary:   Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at 8 Hours Post-dose on Day 28   [ Time Frame: 8 Hours Post-dose on Day 28 ]
  Show Outcome Measure 75

76.  Primary:   Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at 24 Hours Post-dose on Day 28   [ Time Frame: 24 Hours Post-dose on Day 28 ]
  Show Outcome Measure 76

77.  Primary:   Interleukin-1 Receptor Antagonist (IL-1ra) and Interleukin-15 (IL-15) Levels at Pre-dose on Day 35 or Early Termination   [ Time Frame: Pre-dose on Day 35 or Early Termination ]
  Show Outcome Measure 77

78.  Primary:   Urine Collagen Type II C-telopeptide Fragments (uCTX-II) at Pre-dose on Day 1   [ Time Frame: Pre-dose on Day 1 ]
  Show Outcome Measure 78

79.  Primary:   Urine Collagen Type II C-telopeptide Fragments (uCTX-II) at Pre-dose on Day 10   [ Time Frame: Pre-dose on Day 10 ]
  Show Outcome Measure 79

80.  Primary:   Urine Collagen Type II C-telopeptide Fragments (uCTX-II) at Pre-dose on Day 28   [ Time Frame: Pre-dose on Day 28 ]
  Show Outcome Measure 80

81.  Primary:   Urine Collagen Type II C-telopeptide Fragments (uCTX-II) at 24 Hours Post-dose on Day 28   [ Time Frame: 24 Hours Post-dose on Day 28 ]
  Show Outcome Measure 81

82.  Primary:   Urine Collagen Type II C-telopeptide Fragments (uCTX-II) at Pre-dose on Day 35 or Early Termination   [ Time Frame: Pre-dose on Day 35 or Early Termination ]
  Show Outcome Measure 82

83.  Secondary:   Percentage of Participants Achieving American College of Rheumatology 20% Response   [ Time Frame: Day 28, 35 or Early Termination ]
  Show Outcome Measure 83

84.  Secondary:   Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response   [ Time Frame: Day 28, 35 or Early Termination ]
  Show Outcome Measure 84

85.  Secondary:   Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response   [ Time Frame: Day 28, 35 or Early Termination ]
  Show Outcome Measure 85

86.  Secondary:   Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP])   [ Time Frame: Day -7, 1 (Baseline), 28, 35 or Early Termination ]
  Show Outcome Measure 86

87.  Secondary:   Change From Baseline in Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Day 28 and 35   [ Time Frame: Day 1 (Baseline), 28, 35 or Early Termination ]
  Show Outcome Measure 87

88.  Secondary:   Percentage of Participants With Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) <=3.2 and <2.6   [ Time Frame: Day -7, 1 (Baseline), 28, 35 or Early Termination ]
  Show Outcome Measure 88

89.  Secondary:   Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR])   [ Time Frame: Day -7, 1 (Baseline), 28, 35 or Early Termination ]
  Show Outcome Measure 89

90.  Secondary:   Change From Baseline in Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Day 28 and 35   [ Time Frame: Day 1 (Baseline), 28, 35 or Early Termination ]
  Show Outcome Measure 90

91.  Secondary:   Percentage of Participants With Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) <=3.2 and <2.6   [ Time Frame: Day -7, 1 (Baseline), 28, 35 or Early Termination ]
  Show Outcome Measure 91


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Pfizer ClinicalTrials.gov Call Center
Organization: Pfizer, Inc.
phone: 1-800-718-1021
e-mail: ClinicalTrials.gov_Inquiries@pfizer.com


No publications provided


Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00976599     History of Changes
Other Study ID Numbers: A3921073
Study First Received: September 11, 2009
Results First Received: December 4, 2012
Last Updated: December 4, 2012
Health Authority: United States: Food and Drug Administration